The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from patients with atopic dermatitis

Br J Dermatol. 2018 Oct;179(4):951-958. doi: 10.1111/bjd.16722. Epub 2018 Jul 24.

Abstract

Background: Carriage rates of Staphylococcus aureus on affected skin in atopic dermatitis (AD) are approximately 70%. Increasing disease severity during flares and overall disease severity correlate with increased burden of S. aureus. Treatment in AD therefore often targets S. aureus with topical and systemic antimicrobials.

Objectives: To determine whether antimicrobial sensitivities and genetic determinants of resistance differed in S. aureus isolates from the skin of children with AD and healthy child nasal carriers.

Methods: In this case-control study, we compared S. aureus isolates from children with AD (n = 50) attending a hospital dermatology department against nasal carriage isolates from children without skin disease (n = 49) attending a hospital emergency department for noninfective conditions. Using whole genome sequencing we generated a phylogenetic framework for the isolates based on variation in the core genome, then compared antimicrobial resistance phenotypes and genotypes between disease groups.

Results: Staphylococcus aureus from cases and controls had on average similar numbers of phenotypic resistances per isolate. Case isolates differed in their resistance patterns, with fusidic acid resistance (FusR ) being significantly more frequent in AD (P = 0·009). The genetic basis of FusR also differentiated the populations, with chromosomal mutations in fusA predominating in AD (P = 0·049). Analysis revealed that FusR evolved multiple times and via multiple mechanism in the population. Carriage of plasmid-derived qac genes, which have been associated with reduced susceptibility to antiseptics, was eight times more frequent in AD (P = 0·016).

Conclusions: The results suggest that strong selective pressure drives the emergence and maintenance of specific resistances in AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Anti-Infective Agents, Local / administration & dosage
  • Anti-Infective Agents, Local / adverse effects*
  • Carrier State / diagnosis
  • Carrier State / drug therapy
  • Carrier State / microbiology
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Dermatitis, Atopic / diagnosis
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / microbiology*
  • Drug Resistance, Bacterial / drug effects*
  • Drug Resistance, Bacterial / genetics
  • Female
  • Healthy Volunteers
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Microbial Sensitivity Tests
  • Mutation
  • Nasal Mucosa / microbiology
  • Peptide Elongation Factor G / genetics
  • Peptide Elongation Factor G / isolation & purification
  • Severity of Illness Index
  • Skin / microbiology
  • Staphylococcal Skin Infections / diagnosis
  • Staphylococcal Skin Infections / drug therapy
  • Staphylococcal Skin Infections / microbiology*
  • Staphylococcus aureus / isolation & purification
  • Staphylococcus aureus / physiology*

Substances

  • Anti-Infective Agents, Local
  • FusA protein, Staphylococcus aureus
  • Peptide Elongation Factor G